IN8BIO INC. - COMMON STOCK

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 Aug 2022 15:15:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

11 Aug 2022 21:05:00 By Nasdaq GlobeNewswire

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

27 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

21 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

12 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio to Present at July Investor and Scientific Conferences

30 Jun 2022 15:15:00 By Nasdaq GlobeNewswire

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

06 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

17 May 2022 06:00:02 By Nasdaq GlobeNewswire

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

05 May 2022 07:00:02 By Nasdaq GlobeNewswire

IN8bio to Present at May Investor and Scientific Conferences

04 May 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

13 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

IN8bio to Present at April Investor and Scientific Conferences

05 Apr 2022 15:15:00 By Nasdaq GlobeNewswire

IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

28 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

17 Mar 2022 15:15:00 By Nasdaq GlobeNewswire

IN8bio to present at March Investor and Scientific Conferences

04 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

10 Feb 2022 16:36:28 By Nasdaq GlobeNewswire

IN8bio to Present at Upcoming January Investor Conferences

10 Jan 2022 06:00:04 By Nasdaq GlobeNewswire

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

06 Jan 2022 06:00:01 By Nasdaq GlobeNewswire